IRIS Accounts Production v25.1.0.734 13334814 Board of Directors Board of Directors 1.5.23 30.4.24 30.4.24 false true false false false true false Ordinary shares 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh133348142023-04-30133348142024-04-30133348142023-05-012024-04-30133348142022-04-30133348142022-05-012023-04-30133348142023-04-3013334814ns15:EnglandWales2023-05-012024-04-3013334814ns14:PoundSterling2023-05-012024-04-3013334814ns10:Director12023-05-012024-04-3013334814ns10:Director22023-05-012024-04-3013334814ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3013334814ns10:SmallEntities2023-05-012024-04-3013334814ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3013334814ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3013334814ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3013334814ns10:FullAccounts2023-05-012024-04-301333481412023-05-012024-04-3013334814ns10:OrdinaryShareClass12023-05-012024-04-3013334814ns5:CurrentFinancialInstruments2024-04-3013334814ns5:CurrentFinancialInstruments2023-04-3013334814ns5:Non-currentFinancialInstruments2024-04-3013334814ns5:Non-currentFinancialInstruments2023-04-3013334814ns5:ShareCapital2024-04-3013334814ns5:ShareCapital2023-04-3013334814ns5:RetainedEarningsAccumulatedLosses2024-04-3013334814ns5:RetainedEarningsAccumulatedLosses2023-04-3013334814ns10:RegisteredOffice2023-05-012024-04-3013334814ns5:NetGoodwill2023-05-012024-04-3013334814ns5:IntangibleAssetsOtherThanGoodwill2023-05-012024-04-3013334814ns5:NetGoodwill2023-04-3013334814ns5:IntangibleAssetsOtherThanGoodwill2023-04-3013334814ns5:NetGoodwill2024-04-3013334814ns5:IntangibleAssetsOtherThanGoodwill2024-04-3013334814ns5:NetGoodwill2023-04-3013334814ns5:IntangibleAssetsOtherThanGoodwill2023-04-3013334814ns5:LandBuildings2023-04-3013334814ns5:PlantMachinery2023-04-3013334814ns5:LandBuildings2023-05-012024-04-3013334814ns5:PlantMachinery2023-05-012024-04-3013334814ns5:LandBuildings2024-04-3013334814ns5:PlantMachinery2024-04-3013334814ns5:LandBuildings2023-04-3013334814ns5:PlantMachinery2023-04-3013334814ns5:WithinOneYearns5:CurrentFinancialInstruments2024-04-3013334814ns5:WithinOneYearns5:CurrentFinancialInstruments2023-04-3013334814ns10:OrdinaryShareClass12024-04-30
REGISTERED NUMBER: 13334814 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 April 2024

for

Lasaderm Treatments Limited

Lasaderm Treatments Limited (Registered number: 13334814)






Contents of the Financial Statements
for the Year Ended 30 April 2024




Page

Balance Sheet 1

Notes to the Financial Statements 3


Lasaderm Treatments Limited (Registered number: 13334814)

Balance Sheet
30 April 2024

30.4.24 30.4.23
Notes £    £    £   
FIXED ASSETS
Intangible assets 4 125,355 143,104
Tangible assets 5 49,330 57,574
174,685 200,678

CURRENT ASSETS
Debtors 6 32,670 31,911
Cash at bank 23,091 26,460
55,761 58,371
CREDITORS
Amounts falling due within one year 7 51,174 68,370
NET CURRENT ASSETS/(LIABILITIES) 4,587 (9,999 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

179,272

190,679

CREDITORS
Amounts falling due after more than one
year

8

206,978

192,895
NET LIABILITIES (27,706 ) (2,216 )

CAPITAL AND RESERVES
Called up share capital 9 100 100
Retained earnings (27,806 ) (2,316 )
SHAREHOLDERS' FUNDS (27,706 ) (2,216 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Lasaderm Treatments Limited (Registered number: 13334814)

Balance Sheet - continued
30 April 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 29 April 2025 and were signed on its behalf by:




Dr S Merali - Director



Dr A O Nnadi - Director


Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements
for the Year Ended 30 April 2024

1. STATUTORY INFORMATION

Lasaderm Treatments Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 13334814

Registered office: Primera Accountants Limited
First Floor Spitalfields House
Stirling Way
Borehamwood
WD6 2FX

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued

Intangible fixed assets - goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

Intangible fixed assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Intellectual PropertyOver 10 years on straight line basis

Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvementsOver the term of the lease
Plant and equipment15% straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of fixed assets
At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

Leases
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2023 - 5 ) .

Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

4. INTANGIBLE FIXED ASSETS
Other
intangible
Goodwill assets Totals
£    £    £   
COST
At 1 May 2023
and 30 April 2024 127,000 50,000 177,000
AMORTISATION
At 1 May 2023 24,321 9,575 33,896
Charge for year 12,735 5,014 17,749
At 30 April 2024 37,056 14,589 51,645
NET BOOK VALUE
At 30 April 2024 89,944 35,411 125,355
At 30 April 2023 102,679 40,425 143,104

5. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 May 2023 37,345 38,544 75,889
Additions - 1,515 1,515
At 30 April 2024 37,345 40,059 77,404
DEPRECIATION
At 1 May 2023 9,518 8,797 18,315
Charge for year 3,744 6,015 9,759
At 30 April 2024 13,262 14,812 28,074
NET BOOK VALUE
At 30 April 2024 24,083 25,247 49,330
At 30 April 2023 27,827 29,747 57,574

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Other debtors 32,670 31,911

Lasaderm Treatments Limited (Registered number: 13334814)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.4.24 30.4.23
£    £   
Bank loans and overdrafts - 5,000
Trade creditors 5,544 9,210
Taxation and social security 750 1,187
Other creditors 44,880 52,973
51,174 68,370

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
30.4.24 30.4.23
£    £   
Bank loans - 12,917
Other creditors 206,978 179,978
206,978 192,895

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30.4.24 30.4.23
value: £    £   
100 Ordinary shares £1 100 100

10. OPERATING LEASE COMMITMENTS

Lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

30.04.2430.04.23
£   £   

320,875366,175

11. RELATED PARTY DISCLOSURES

Included within costs of sales are costs of £65,615 (2023: £66,949) for services provided by companies in which the directors have an interest.

Included within other creditors are amounts of £223,128 (2023: £190,064) owed to companies in which the directors have an interest.

12. ULTIMATE CONTROLLING PARTY

The company is controlled by the directors by virtue of holding its entire issued share capital.